Radiosensitization of HSF-1 Knockdown Lung Cancer Cells by Low Concentrations of Hsp90 Inhibitor NVP-AUY922

被引:19
|
作者
Kuehnel, Annett [1 ,2 ]
Schilling, Daniela [1 ,2 ]
Combs, Stephanie E. [1 ,2 ,3 ]
Haller, Bernhard [4 ]
Schwab, Melissa [5 ]
Multhoff, Gabriele [1 ,5 ]
机构
[1] Tech Univ Munich, Klinikum Rechts Isar, Dept Radiat Oncol, Ismaninger Str 22, D-81675 Munich, Germany
[2] Helmholtz Zentrum Munchen, DRS, IRM, Ingolstadter Landstr 1, D-85764 Neuherberg, Germany
[3] DKTK, Partner Site Munich, D-81675 Munich, Germany
[4] Tech Univ Munich, Klinikum Rechts Isar, Inst Med Informat Stat & Epidemiol, Ismaningerstr 21, D-81675 Munich, Germany
[5] Tech Univ Munchen TranslaTUM, Klinikum Rechts Isar, Ctr Translat Canc Res, Einsteinstr 25, D-81675 Munich, Germany
关键词
heat shock factor (HSF-1) knockdown; heat shock proteins 70 and 27; radiosensitization; Hsp90 inhibitor NVP-AUY922; homologous recombination (HR); HEAT-SHOCK PROTEINS; SENSITIZING TUMOR-CELLS; DNA-DAMAGE RESPONSE; IN-VITRO; CHAPERONE INHIBITORS; RADIATION RESPONSE; FACTOR-1; 17-ALLYLAMINO-17-DEMETHOXYGELDANAMYCIN; GELDANAMYCIN; EXPRESSION;
D O I
10.3390/cells8101166
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The inhibition of heat shock protein 90 (Hsp90) a molecular chaperone for multiple oncogenic client proteins is considered as a promising approach to overcome radioresistance. Since most Hsp90 inhibitors activate HSF-1 that induces the transcription of cytoprotective and tumor-promoting stress proteins such as Hsp70 and Hsp27, a combined approach consisting of HSF-1 knockdown (k.d.) and Hsp90 inhibition was investigated. A specific HSF-1 k.d. was achieved in H1339 lung cancer cells using RNAi-Ready pSIRENRetroQ vectors with puromycin resistance. The Hsp90 inhibitor NVP-AUY922 was evaluated at low concentrations-ranging from 1-10 nM-in control and HSF-1 k.d. cells. Protein expression (i.e., Hsp27/Hsp70, HSF-1, pHSF-1, Akt, beta-actin) and transcriptional activity was assessed by western blot analysis and luciferase assays and radiosensitivity was measured by proliferation, apoptosis (Annexin V, active caspase 3), clonogenic cell survival, alkaline comet, gamma H2AX, 53BP1, and Rad51 foci assays. The k.d. of HSF-1 resulted in a significant reduction of basal and NVP-AUY922-induced Hsp70/Hsp27 expression levels. A combined approach consisting of HSF-1 k.d. and low concentrations of the Hsp90 inhibitor NVP-AUY922 reduces the Hsp90 client protein Akt and potentiates radiosensitization, which involves an impaired homologous recombination mediated by Rad51. Our findings are key for clinical applications of Hsp90 inhibitors with respect to adverse hepatotoxic effects.
引用
收藏
页数:16
相关论文
共 50 条
  • [21] Heat-shock protein (Hsp) 70 inhibition enhances the effect of the Hsp90 inhibitor NVP-AUY922 on melanoma cells
    Yeramian, A.
    Vea, A.
    Santacana, M.
    Matias-Guiu, X.
    Marti, R. M.
    BRITISH JOURNAL OF DERMATOLOGY, 2014, 171 (03) : E48 - E48
  • [22] Heat-shock protein (Hsp)70 inhibition enhances the effect of the Hsp90 inhibitor NVP-AUY922 on melanoma cells
    Yeramian, A.
    Vea, A.
    Santacana, M.
    Matias-Guiu, X.
    Marti, R. M.
    BRITISH JOURNAL OF DERMATOLOGY, 2014, 171 : 36 - 36
  • [23] Antitumor Effect of Novel HSP90 Inhibitor NVP-AUY922 against Oral Squamous Cell Carcinoma
    Okui, Tatsuo
    Shimo, Tsuyoshi
    Hassan, Nur Mohammad Monsur
    Fukazawa, Takuya
    Kurio, Naito
    Takaoka, Munenori
    Naomoto, Yoshio
    Sasaki, Akira
    ANTICANCER RESEARCH, 2011, 31 (04) : 1197 - 1204
  • [24] Modeling spheroid growth, PET tracer uptake, and treatment effects of the Hsp90 inhibitor NVP-AUY922
    Bergstrom, Mats
    Monazzam, Azita
    Razifar, Pasha
    Ide, Susan
    Josephsson, Raymond
    Langstrom, Bengt
    JOURNAL OF NUCLEAR MEDICINE, 2008, 49 (07) : 1204 - 1210
  • [25] Strong anti-tumor effect of NVP-AUY922, a novel Hsp90 inhibitor, on non-small cell lung cancer
    Ueno, Tsuyoshi
    Tsukuda, Kazunori
    Toyooka, Shinichi
    Ando, Midori
    Takaoka, Munenori
    Soh, Junichi
    Asano, Hiroaki
    Maki, Yuho
    Muraoka, Takayuki
    Tanaka, Norimitsu
    Shien, Kazuhiko
    Furukawa, Masashi
    Yamatsuji, Tomoki
    Kiura, Katsuyuki
    Naomoto, Yoshio
    Miyoshi, Shinichiro
    LUNG CANCER, 2012, 76 (01) : 26 - 31
  • [26] Hsp90 inhibitor NVP-AUY922 enhances radiation sensitivity of tumor cell lines under hypoxia
    Djuzenova, Cholpon S.
    Blassl, Christina
    Roloff, Konstanze
    Kuger, Sebastian
    Katzer, Astrid
    Niewidok, Natalia
    Guenther, Nadine
    Polat, Buelent
    Sukhorukov, Vladimir L.
    Flentje, Michael
    CANCER BIOLOGY & THERAPY, 2012, 13 (06) : 425 - 434
  • [27] Bioluminescence Imaging to Monitor the Effects of the Hsp90 Inhibitor NVP-AUY922 on NF-κB Pathway in Endometrial Cancer
    Andree Yeramian
    Virginia García
    Laura Bergadà
    Mónica Domingo
    Maria Santacana
    Joan Valls
    Montserrat Martinez-Alonso
    José-Antonio Carceller
    Antonio Llombart Cussac
    Xavier Dolcet
    Xavier Matias-Guiu
    Molecular Imaging and Biology, 2016, 18 : 545 - 556
  • [28] Bioluminescence Imaging to Monitor the Effects of the Hsp90 Inhibitor NVP-AUY922 on NF-κB Pathway in Endometrial Cancer
    Yeramian, Andree
    Garcia, Virginia
    Bergada, Laura
    Domingo, Monica
    Santacana, Maria
    Valls, Joan
    Martinez-Alonso, Montserrat
    Carceller, Jose-Antonio
    Llombart Cussac, Antonio
    Dolcet, Xavier
    Matias-Guiu, Xavier
    MOLECULAR IMAGING AND BIOLOGY, 2016, 18 (04) : 545 - 556
  • [29] The HSP90 inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cells
    Canonici, Alexandra
    Qadir, Zulfiqar
    Conlon, Neil T.
    Collins, Denis M.
    O'Brien, Neil A.
    Walsh, Naomi
    Eustace, Alex J.
    O'Donovan, Norma
    Crown, John
    INVESTIGATIONAL NEW DRUGS, 2018, 36 (04) : 581 - 589
  • [30] Pharmakokinetic/phamacodynamic relationship in human xenograft models and PBMC's treated with the Hsp90 inhibitor NVP-AUY922
    Jensen, M. R.
    Ide, S.
    Brueggen, J.
    Schoepfer, J.
    Motwani, M.
    Wang, X.
    Radimerski, T.
    Quadt, C.
    Garcia-Echeverria, C.
    Chene, P.
    EJC SUPPLEMENTS, 2008, 6 (12): : 50 - 50